Patents by Inventor Peter Madsen

Peter Madsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon antagonists/inverse agonists
    Patent number: 6953812
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: October 11, 2005
    Assignee: Novo Nordisk, Inc.
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Glucagon antagonists/inverse agonists
    Publication number: 20050203108
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 15, 2005
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Christensen, Behrend Lundt, Ulla Sidelmann, Henning Thogersen, Anthony Ling, Michael Plewe, Larry Truesdale, Anker Jogensen, Janos Kodra, Shenghua Shi
  • Non-peptide GLP-1 agonists
    Patent number: 6927214
    Abstract: Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 9, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Min Teng, Larry Kenneth Truesdale, Dilip Bhumralkar, Dan Kiel, Michael D. Johnson, Christine Thomas, Anker Steen Jorgensen, Peter Madsen, Preben Houlberg Olesen, Liselotte Bjerre Knudsen, Ingrid Vivika Petterson, Johannes Cornelis de Jong, Carsten Behrens, Janos Tibor Kodra, Jesper Lau
  • Modular furniture system
    Publication number: 20050162051
    Abstract: A modular furniture system based on a fundamental building block is provided. The building block, or cell, includes first and second end plates and at least one horizontal support beam. A plurality of stacked and/or side-by-side cells provide a framework that can be arranged in an almost limitless number of ways. The cells serve as both storage space and division between neighboring work spaces, thus conserving raw materials and recovering floor space. The cells further provide raceways for concealing electrical wires and data cables, and are adapted for supporting work surfaces and connecting to vertical panels. The cells are adapted to receive various storage components, such as drawers, which may be inserted from both a front side and a back side of each cell. The cells are also adapted to receive tiles, which may cover open sides of each cell and/or cover the end plates of each cell. The tiles may provide any of a multitude of different aesthetic and functional surfaces.
    Type: Application
    Filed: May 1, 2003
    Publication date: July 28, 2005
    Inventors: Peter Madsen, William Pokletar
  • Glucagon antagonists/inverse agonists
    Patent number: 6881746
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: April 19, 2005
    Assignee: Novo Nordick A/S
    Inventors: Jesper Lau, Inge Thoger Christensen, Peter Madsen, Paw Bloch, Carsten Behrens, Janos Tibor Kodra, Poul Enrico Nielsen
  • Glucagon antagonists/inverse agonists
    Patent number: 6875760
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: April 5, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jøgensen, Janos Tibor Kodra, Shenghua Shi
  • Stabilised insulin compositions
    Publication number: 20050065066
    Abstract: The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The resulting preparations have improved physical and chemical stability.
    Type: Application
    Filed: April 16, 2004
    Publication date: March 24, 2005
    Inventors: Niels Kaarsholm, Peter Madsen, Morten Schlein, Helle Olsen, Svend Havelund, Dorte Steensgaard, Svend Ludvigsen, Palle Jakobsen, Anders Petersen, Gerd Schluckebier
  • Glucagon antagonists/inverse agonists
    Publication number: 20050059611
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: October 12, 2004
    Publication date: March 17, 2005
    Applicant: Novo Nordisk A/S
    Inventors: Anker Jorgensen, Peter Madsen
  • Glucagon antagonists/inverse agonists
    Patent number: 6821960
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: November 23, 2004
    Assignee: Noyo Nordisk Pharmaceuticals, Inc.
    Inventors: Anker Steen Jørgensen, Peter Madsen
  • Novel glucagon antagonists
    Publication number: 20040152750
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 15, 2003
    Publication date: August 5, 2004
    Inventors: Janos Tibor Kodra, Carsten Behrens, Peter Madsen, Anker Steen Jorgensen, Inger Thoger Christensen
  • Glucagon antagonists
    Patent number: 6762318
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: July 13, 2004
    Assignee: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Peter Madsen, Jesper Lau, Anker Steen Jorgensen, Inge Thoger Christensen
  • Glucagon antagonists/inverse agonists
    Publication number: 20040127560
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: November 13, 2003
    Publication date: July 1, 2004
    Inventors: Peter Madsen, Jesper Lau, Anthony Ling
  • Glucagon antagonists/inverse agonists
    Publication number: 20040116483
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: September 9, 2003
    Publication date: June 17, 2004
    Inventors: Carsten Behrens, Jesper Lau, Peter Madsen
  • Glucagon antagonists/inverse agonists
    Patent number: 6706744
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: March 16, 2004
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Jesper Lau, Anthony Ling
  • Glucagon antagonists/inverse agonists
    Publication number: 20040024045
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Application
    Filed: February 24, 2003
    Publication date: February 5, 2004
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Novel glucagon antagonists/inverse agonists
    Publication number: 20040014789
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 22, 2004
    Inventors: Jesper Lau, Inge Thoger Christensen, Peter Madsen, Paw Bloch, Carsten Behrens, Janos Tibor Kodra, Poul Enrico Nielsen
  • Novel glucagon antagonists
    Publication number: 20030236292
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Janos Tibor Kodra, Peter Madsen, Jesper Lau, Anker Steen Jorgensen, Inge Thoger Christensen
  • Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
    Publication number: 20030229120
    Abstract: Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.
    Type: Application
    Filed: May 14, 2003
    Publication date: December 11, 2003
    Inventors: Helle Birk Olsen, Niels C. kaarsholm, Peter Madsen, Soren Ostergaard, Svend Ludvigsen, Palle Jakobsen, Anders Klarskov Petersen, Dorte Bjerre Steensgaard
  • Glucagon receptor antagonists/inverse agonists
    Publication number: 20030229128
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, type 1 diabetes, type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: December 18, 2002
    Publication date: December 11, 2003
    Inventors: Peter Madsen, Carsten Behrens
  • Glucagon antagonists/inverse agonists
    Publication number: 20030220350
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: August 30, 2002
    Publication date: November 27, 2003
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi